Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. (Q53278107)

12 May 2018

title

Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. (English)

1 reference

12 May 2018

1 reference

3

1 reference

12 May 2018

Kensei Tobinai

1

object named as

Kensei Tobinai

1 reference

12 May 2018

author name string

Michinori Ogura

2

1 reference

12 May 2018

Toshiki Uchida

4

1 reference

12 May 2018

Takashi Watanabe

5

1 reference

12 May 2018

Takashi Oyama

6

1 reference

12 May 2018

Dai Maruyama

7

1 reference

12 May 2018

Tatsuya Suzuki

8

1 reference

12 May 2018

Masakazu Mori

9

1 reference

12 May 2018

Masanobu Kasai

10

1 reference

12 May 2018

Damien Cronier

11

1 reference

12 May 2018

James E Wooldridge

12

1 reference

12 May 2018

Minori Koshiji

13

1 reference

12 May 2018

publication date

12 January 2011

1 reference

12 May 2018

published in

Cancer Science

1 reference

12 May 2018

volume

102

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

page(s)

432-438

1 reference

12 May 2018

Follicular lymphoma in the United States: first report of the national LymphoCare study

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

New treatment options have changed the survival of patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Improved survival of follicular lymphoma patients in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B‐cell non‐Hodgkin lymphoma: 7‐year follow‐up results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Follicular lymphoma international prognostic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1349-7006.2010.01809.X

10.1111/J.1349-7006.2010.01809.X

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018